StoneX reiterates Buy on MiniMed stock ahead of earnings
StoneX reiterated a Buy rating and $20.00 price target for MiniMed Group (MMED) ahead of its Q1 earnings. The company expects Q1 2027 revenue of $829M and EBITDA of $117M, aligning with consensus. Analysts forecast 10% organic revenue growth and 16% EBITDA margins for fiscal 2027, driven by product demand and cost efficiencies. MMED trades near its 52-week high at $21.37.
How this was made
The 30-second read
Why it matters
Near-term positioning may be influenced by the specific consensus-like forecast numbers ($117M adjusted EBITDA, ~$829M revenue) and the stated catalyst path (Vivera algorithm trial completion, Fit patch pump FDA submission, and 2027 launches).
Market read
This is a pre-earnings analyst reiteration with concrete forecast figures and a catalyst timeline, useful for trade planning into the earnings event.
What to watch
The article does not introduce new trial results or regulatory decisions; traders may discount the catalyst list if prior guidance has slipped or if competitive/coverage dynamics change.
Background
StoneX reiterates Buy and a $20 price target on MiniMed Group ahead of its fiscal first-quarter earnings, referencing forecasted EBITDA/revenue and a turnaround narrative.
Ticker impact
StoneX reiterated a Buy on MiniMed Group ahead of fiscal first-quarter earnings, citing $117M adjusted EBITDA and $829M revenue forecasts.
Bias toward continued support for MMED into earnings, with upside skew if results align with the $117M/$829M setup and catalyst timelines hold.
The article is primarily an analyst reiteration plus forward-looking catalyst list, not a new company disclosure; however, it includes specific forecast figures and dates that can influence positioning ahead of the print.
Market effects
Could modestly support sentiment around diabetes device and closed-loop insulin delivery ecosystem names ahead of earnings season.
Limited, mostly US small/mid-cap medtech sentiment.
Low; catalysts are company-specific (FDA submission and product launches) rather than a global regulatory shift.
Counterpoint
The piece is largely reiteration and model-based optimism; execution risk remains around clinical trial completion, FDA submission timing, and commercial uptake of Flex and Fit patch pump.
Key entities
- companyMiniMed Group
NASDAQ-listed diabetes technology company discussed as the subject of StoneX’s reiteration ahead of earnings.
- analyst_firmStoneX
Reiterated Buy rating and $20.00 price target; provided forecast and catalyst framing.
- productsMiniMed Flex AID system and MiniMed Go smart insulin pen
New products mentioned as integrating with the company app ecosystem, supporting the growth narrative.
